Formycon Signs APAC Eylea Biosimilar Deal With Taiwan’s Lotus
The Aflibercept Deal Follows A Flurry Of Approvals In The Past Year
Having secured approvals for the Eylea biosimilar in major markets such as the US and Europe, Formycon has signed a fresh licensing deal with Lotus Pharmaceutical, giving away rights to the asset in the APAC region.
